Hugo, González SaldivarFigueiras-Graillet, Lourdes MAnguita, ManuelMarín, FranciscoBertomeu, VicenteRoldán, InmaculadaRuiz, MartínMuñiz, JavierMartínez-Sellés, ManuelFANTASIIA registry investigators (see Appendix)2023-01-252023-01-252016-08-04http://hdl.handle.net/10668/10362Vitamin K antagonists (VKAs) are still largely employed, even in nonvalvular atrial fibrillation (AF). Our aim was to study the clinical profile of octogenarians treated with oral anticoagulation and to study the effect of age on the quality of VKAs anticoagulation. Data are from a prospective national registry in an adult Spanish population of nonvalvular AF. We included 1637 patients who had been receiving VKAs for at least 6months before enrolment. Mean age was 73.8±9.4years. Patients aged >80years (N=429) had a high risk profile with higher risk of stroke and bleeding than younger patients; CHA2DS2-VASc (Cardiac failure, Hypertension, Age>74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p80years (N=429) had a high risk profile with higher risk of stroke and bleeding than younger patients; CHA2DS2-VASc (Cardiac failure, Hypertension, Age>74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p64years), Drugs/alcohol concomitantly) 2.4±0.9 vs. 1.9±1.1, p In this large registry octogenarians with nonvalvular AF had high risk of stroke and bleeding and frequent renal disease. VKAs anticoagulation quality was similar in octogenarians and in younger patients.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AgeAtrial fibrillationOctogenariansTime in therapeutic rangeVitamin K antagonistsAdministration, OralAge FactorsAgedAged, 80 and overAnticoagulantsAtrial FibrillationDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansIncidenceMaleProspective StudiesRegistriesRisk AssessmentRisk FactorsSpainStrokeSurvival RateTreatment Outcomeresearch article27532238open access10.1016/j.ijcard.2016.08.0041874-1754https://ruc.udc.es/dspace/bitstream/2183/17273/3/Saldivar_OralAnticoagulation.pdf